Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene's Q2 Net Loss Widens 11 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian diagnostics firm Med BioGene today said its net loss rose 11 percent in the second quarter.

For the three months ended June 30, the company posted no revenues, the same as a year ago. Net loss totaled C$551,910 ($524,266), or C$0.01 per share for the quarter, compared to C$497,503, C$0.01 per share, a year ago.

The firm filed a preliminary prospectus with the US Securities and Exchange Commission in late-December to float its shares on the Nasdaq, and today said that it has incurred a total of C$929,446 in expenses related to the IPO.

R&D spending for the quarter rose 30 percent C$248,840 during the quarter from C$190,863, and SG&A spending dipped 2 percent to C$282,804 from C$286,888 in the year-ago period.

The Vancouver, B.C., company said it had cash and cash equivalents of C$493,660 as of June 30.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.